ADC Therapeutics SA filed a Form 8-K on November 4, 2026, disclosing new and updated clinical trial data for ZYNLONTA ahead of the 68th American Society of Hematology Annual Meeting, along with preliminary financial estimates for the period ended September 30, 2026.

Key Highlights

  • LOTIS-7 overall response rate: Among 97 efficacy-evaluable patients at the ZYNLONTA 150 µg/kg starting dose combined with glofitamab, the ORR was 88.7% (n=86) and the complete response rate was 75.3% (n=73), as of the June 15, 2026 data cutoff.
  • Primary refractory and CAR-T subgroups: In patients with primary refractory disease (n=54), ORR was 78.4% and CRR was 64.7%; among patients previously treated with CAR-T therapy (n=28), ORR was 74.1% and CRR was 63.0%.
  • Marginal zone lymphoma Phase 2 trial: Among 43 efficacy-evaluable patients, ORR was 93% and CRR was 74.4%, with a two-year PFS rate of 90.8% at a median follow-up of 23.2 months, as of the July 1, 2026 data cutoff.
  • Safety profile - LOTIS-7: CRS was observed in 32% of treated patients, predominantly Grade 1 (25.2%) or Grade 2 (5.8%); one Grade 3 CRS event and three Grade 5 treatment-emergent adverse events were reported.
  • Preliminary financials included: The filing states the presentation includes preliminary revenue estimates for the three and nine months ended September 30, 2026, and preliminary cash and cash equivalents as of September 30, 2026, including estimates of cash used for one-time severance and retention payments during that quarter.
  • ASH presentations: Data will be shared across multiple abstracts, including five oral presentations, at the meeting taking place December 12-15, 2026, in New Orleans, Louisiana.

ZYNLONTA Clinical Data Details Disclosed by ADC Therapeutics

According to the filing, ADC Therapeutics SA (NYSE:ADCT) reported updated data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with glofitamab in relapsed or refractory large B cell lymphoma. The data cutoff was June 15, 2026. The filing states that patients had received a median of one prior treatment (range: 1-5), and 52.4% (n=54) had primary refractory disease. Among the 97 efficacy-evaluable patients, 28 patients converted to complete responses over time, from stable disease (n=1) or partial response (n=27). Of patients who achieved a complete response, 84.9% (n=62) remained in complete response as of the data cutoff. At a median follow-up of 10.35 months, median duration of response, duration of complete response, and PFS had not been reached; the 6-month and 12-month duration of complete response rates were 81.9% and 79.0%, respectively.

The filing also disclosed data from a Phase 2 investigator-initiated trial of ZYNLONTA in relapsed or refractory marginal zone lymphoma. As of the July 1, 2026 data cutoff, patients had received a median of two prior treatments, with 37% having primary refractory disease and 42% having experienced disease progression within 24 months of initial therapy. The duration of response rate at 24 months was 90.9%. Among 46 treated patients, adverse events were described as predominantly Grade 1-2, with Grade 3 AEs reported in 23 patients (50%) and Grade 4 AEs in five patients (10.9%). Four patients required dose reductions.

Regarding the preliminary financial figures, the filing noted that "management made a number of complex and subjective judgments and estimates" in preparing them, that the actual results for those periods "have not yet been finalized by management," and that "subsequent information or events may lead to material differences between the foregoing preliminary financial results and those reported in the Company's subsequent regulatory filings." The filing explicitly cautions that "investors should not place undue reliance on these preliminary financial results."

What Was Disclosed

ADC Therapeutics filed a Form 8-K on November 4, 2026, disclosing ZYNLONTA clinical trial data for the LOTIS-7 combination trial and a marginal zone lymphoma investigator-initiated trial, along with preliminary, unfinalized revenue and cash estimates for the period ended September 30, 2026.